The approval could help spur a turnaround for Novo after a rocky year of sliding shares, profit warnings, and slowing sales of its injectable Wegovy. — AFP
NEW YORK: The US Food and Drug Administration approves Novo Nordisk’s weight-loss pill, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground on rival Eli Lilly.
The pill is 25 mg of semaglutide, the same active ingredient in injectable Wegovy and Ozempic, and will be sold under the brand name Wegovy. Novo already sells an oral semaglutide for type 2 diabetes, Rybelsus.
